Search

Joseph Blondeau Antibiotic resistance is not going to go away in a hurry, but can we at least make it as difficult as possible for bacteria to overcome the drugs they face? Joseph Blondeau told the co

Thomas File Thomas File, Summa Health System, Akron, Ohio Community Associated Pneumonia is a sizeable problem for health systems, and what is more, some strains of the frequent culprit – strept

Hank Balfour Hank Balfour, University of Minnesota, Minneapolis Infectious mononucleosis, also known as the kissing disease, is caused Epstein Barr Virus, or EBV; so, can we effectively treat, and pre

Lance Peterson Lance Peterson, Evanston Northwestern Healthcare, Illinois The bacterium clostridium difficile that can cause diarrhoea in hospital patients is making a resurgence. It’s potential

Michele Pearson Michele Pearson, Centers for Disease Control and Prevention, Atlanta A community-wide approach is needed to combat MRSA according to a new assessment presented to the conference in Was

Ross Davidson Ross Davidson, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia The use of the antimalarial chloroquine could provide the selective pressure for E.coli to develop fluoroqu

Barbara Trautner Barbara Trautner, Baylor College of Medicine, Houston When patients with spinal cord injury rely on urinary catheters for bladder drainage, this may lead to one or more urinary tract

Yehuda Carmeli Yehuda Carmeli, Beth Israel Deaconess Medical Center, Boston The Washington DC conference also heard about a hospital infection that has had a worryingly low profile: acinetobacter baum

Daniel Diekema, University of Iowa, Iowa City A large, global survey of candida distribution and drug susceptibility reported at the ICAAC found that fluconazole resistance among candida glabrata appe

Louis Bourgeois, Johns Hopkins University, Baltimore Among the various experiences when visiting a developing country: there’s amazement at the sounds and the colour; delight at the warmth of th

Roy Gulick, Weill Cornell Medical College, New York Although the logic in antiretroviral HIV therapy has, for some years, been that two drugs are better than one; and three are better than two, this h

Timothy Wilkin Timothy Wilkin, Weill Cornell Medical College, New York A protease inhibitor, currently known as TMC114 has been tested in the POWER II study among some 300 patients who had failed mult